further study. Animal studies of the carbonic anhydrase inhibitors such as zonisamide have been shown to cause fetal abnormalities at blood levels similar to those found in the human population. Data from Dr. Ohtahara's presentation supported these findings. Within the study population, four women were treated with zonisamide polytherapy and 2 delivered babies with fetal abnormalities. For this reason, we need additional data in that arena.
More information is also needed on the subject of hypohidrosis and weight loss resulting from anorexia associated with zonisamide treatment. Some valuable information can be obtained by asking our patients specific questions about the severity and onset of these symptoms.
For example, it is important to know when the sweating and fever associated with hypohidrosis occur, which patients are at the greatest risk, and which treatments are most effective. These are important details because as dose-related adverse effects are treated much differently than idiopathic effects, which may require the drug to be stopped immediately. These patient-centered questions should be more clearly defined in the coming months.
Overall, the 10 years of Japanese experience with zonisamide combined with the current US studies provide a solid framework for the future use of zonisamide in the United States.
